The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
List view / Grid view
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
Scientists have developed a technology that can improve targeting specific organs and tissue types in gene therapy.
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
Scientists have gained deeper knowledge about the mislocalisation of a protein, providing a possible therapeutic target that could have implications in treating dementia.
A molecular cage, developed for use during cryo-EM, has provided researchers with new insights into a key cancer protein.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
Artificial intelligence was shown to predict the 3D shapes of RNA molecules, which could significantly advance RNA therapeutics.
Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
Researchers have developed a vaccine using stem cells that protected mice injected with pancreatic cancer cells from developing tumours.
After screening 4,500 compounds using induced pluripotent stem cells, researchers have identified one lead that could treat pulmonary arterial hypertension.
DTR's Victoria Rees interviews Payton Weidenbacher from Stanford University, who discusses a new potential SARS-CoV-2 vaccine that the team he works on developed using nanotechnology.
Researchers have used nanobodies to act as an assistant to CRISPR, bringing in effectors to turn specific genes on and off.
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.